ArticleThe Hastings Center report2021
Pediatric Off-Label Use of Covid-19 Vaccines: Ethical and Legal Considerations.
Article in The Hastings Center report, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Do we need to vaccinate every child against COVID-19: What evidence suggests-A systematic review of opinions.Frontiers in public health · 2022Pooled it
- Navigating the ethical terrain: Off-label and experimental treatments in medical case reports.World journal of methodology · 2025Article
- Off-label prescription of BNT162b2 mRNA COVID-19 vaccine to <5-year-old children in the European Union.Acta paediatrica (Oslo, Norway : 1992) · 2023Article
- Pediatric Off-Label COVID-19 Vaccination: The Concerns of Healthcare Professionals in Pakistan.Vaccines · 2022Article
- Little patients, large risks: An overview on patient safety management in pediatrics settings.Frontiers in pediatrics · 2022Article
- Pediatric Off-Label Use of Covid-19 Vaccines: Ethical and Legal Considerations.The Hastings Center report · 2021Article
- The COVID-19 pandemic in children and young people during 2020-2021: A complex discussion on vaccination.Journal of global healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
When the U.S. Food and Drug Administration fully approved the Pfizer-BioNTech Covid-19 vaccine for people sixteen and older, questions arose. Parents, pediatricians, and the media wondered whether Covid-19 vaccines could be used off-label-and whether they should be. The American Academy of Pediatrics cautioned against pediatric off-label use of the vaccine, and the vaccine provider agreement from the Centers for Disease Control and Prevention appears to prohibit it. After briefly contextualizing ethical and legal precedents regarding off-label use, we offer an analysis of the ethical permissibility of and considerations for pediatric off-label Covid-19 vaccination based on individual benefits, risks, and available alternatives. Our analysis challenges the ethics of a blanket prohibition on off-label pediatric Covid-19 vaccination, as it limits clinician ability to provide care they may determine to be clinically and ethically appropriate. At the same time, our analysis acknowledges that Covid-19 creates population-level ethical considerations that are at times in tension with individual health interests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.